Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CordIn in Hemoglobinopathies
NCT02504619Phase 2Terminated
- Sponsor
- Gamida Cell
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of CordIn in sickle cell disease (SCD) and thalassemia, sponsored by Gamida Cell. Primary endpoints: Number of Participants With no Acute Toxicity Associated With the Infusion of CordIn at 24 hours and Percentage of Patients With Donor-derived Engraftment at 42 days. Started Apr 2016; status: terminated.
02
Drugs
CordIn
03
Conditions
sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT02504619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504619.